טוען...
Combination therapy for metastatic renal cell carcinoma
Current therapy for metastatic clear cell renal cell carcinoma (RCC) consists of the serial administration of single agents. Combinations of VEGF and mTOR inhibitors have been disappointing in previous randomized trials. However, the combination of lenvatinib, a multitargeted agent that inhibits VEG...
שמור ב:
| הוצא לאור ב: | Ann Transl Med |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4791344/ https://ncbi.nlm.nih.gov/pubmed/27047959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2016.01.31 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|